News
-
According to Circassia Pharmaceuticals, the FDA has approved the company’s sNDA for the addition of data from the Phase 4 ASCENT study of the Tudorza Pressair aclidinium bromide DPI in COPD patients showing significant reduction… Read more . . .
-
The Alzheimer’s Drug Discovery Foundation has awarded a grant worth approximately $1.2 million to a team led by Hiroaki Sato and Thomas Schricker at the Research Institute of the McGill University Health Centre (RI-MUHC) for… Read more . . .
-
Auris Medical has announced the initiation of a Phase 1b proof-of-concept study of its AM-201 intranasal betahistine, which the company is developing for the prevention of weight gain and sleepiness in patients taking olanzapine. The… Read more . . .
-
Mundipharma initiates Phase 3 trial of Penthrox in trauma patients rescued from hostile environments
Mundipharma has announced enrollment of the first patient in the Phase 3b METEORA trial of Penthrox inhaled methoxyflurane in patients with limb trauma who have been rescued by helicopter from hostile terrain and are suffering… Read more . . .
-
Synspira Therapeutics, which is developing an inhaled therapy for cystic fibrosis, has announced the appointment of Robert Gallotto as President and CEO. Gallotto was most recently President and co-founder of Alcresta Therapeutics. He previously co-founded… Read more . . .
-
Third Pole Therapeutics, which is developing an inhaled nitric oxide (iNO) generator, has announced a strategic collaboration agreement with Actelion Pharmaceuticals. Details of the agreement were not specified. Third Pole’s iNO platform is designed for… Read more . . .
-
Breath Therapeutics has announced the initiation of Phase 3 studies of its L‑CsA‑i inhaled liposomal cyclosporine A for the treatment of bronchiolitis obliterans. Breath Therapeutics licensed L-CsA-i from PARI in 2017, and the drug is… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) will meet on May 8, 2019 to consider Chiesi’s NDA for Bronchitol mannitol DPI for the treatment of cystic fibrosis. According to Bronchitol developer Pharmaxis, its partner Chiesi… Read more . . .
-
Johnson & Johnson subsidiary Janssen Pharmaceutica has announced that it signed a sponsored research agreement with Monash University’s Monash Institute of Pharmaceutical Sciences (MIPS) for development of an inhaled dry powder oxytocin for the prevention… Read more . . .
-
According to Sosei, Novartis has launched the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in China for the treatment of COPD. Huizheng Technology acquired the Chinese licenses for the inhalers from Novartis… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.